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The Realized Benefits from Bioprospecting in the 
Wake of the Convention on Biological Diversity 
James S. Miller

 
MISSOURI BOTANICAL GARDEN 
In the mid-1980s, the convergence of several technological 
advances led to a serious resurgence of interest in surveying plant 
species for drug development. The emergence of methods to 
miniaturize in-vitro bioassays (a test used to quantify the biological 
effect of a chemical compound or extract against a specific disease 
target) run the bioassays with robotic equipment, and isolate and 
identify active compounds with a speed and precision never before 
possible. This allowed rapid evaluation of large numbers of plant 
samples with an efficiency many times what had ever been possible. 
For example, in the 1960s, the early phase of the Developmental 
Therapeutic Program at the National Cancer Institute (NCI) used 
transplantable tumor cell lines and looked for extracts that prolonged 
life in a statistically significant population of rodents. It often took 
months to evaluate a single extract in an expansive population of 
mice or rats. By the mid-1980s, the same NCI program was running 
sixty-two different cultured cell lines in 96-well microtiter plates and 
was able to evaluate hundreds of extracts per week.
1
 The 
incorporation of these new technologies led to a resurgence in interest 
in natural products, and biological samples were evaluated at a rate 
never before imaginable. 
In 1986, the NCI launched three contracts for the procurement of 
large numbers of plant samples, one each for tropical America, Africa 
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and Madagascar, and tropical Asia.
2
 Each program collected and 
supplied 1,500 samples per year, and the NCI screened and evaluated 
more than 50,000 samples of plants, representing more than 20,000 
plant species, in the next twenty years.
3
 In 1993, the Fogarty 
International Center of the National Institutes of Health (NIH) 
launched the International Cooperative Biodiversity Groups (ICBG), 
funding consortia of biologists collecting samples, others preparing 
and evaluating extracts, chemists determining structures and modes 
of action, and industrial partners providing additional bioassays and 
developmental capabilities.
4
 These programs continue today and they 
have collectively evaluated huge numbers of plants, marine 
invertebrates, insects, and microbial cultures.
5
 Pharmaceutical 
companies also joined the effort to evaluate plants, and large-scale 
screening of natural products took place at Bristol-Myers, Merck, 
Monsanto, Novartis, and Pfizer, among others.
6
 This peak period of 
interest in screening large number of biological samples, primarily 
plants, in the 1980s and 1990s will be referred to here as the 
“bioprospecting surge.” 
At about the same time that interest peaked in natural products, 
discussions were beginning about the legal and ethical frameworks 
that should govern such efforts. In 1992, between June 3rd and June 
14th, the United Nations Conference on Environment and 
Development, often called the Earth Summit, was held in Río de 
Janeiro, Brazil. During the conference, the Convention on Biological 
Diversity (CBD or the “Convention”) opened for signature and was 
entered into force on December 29, 1993.
7
 The Convention 
fundamentally changed the legal status of ownership of biological 
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resources, which had previously been viewed as a common heritage 
open to all countries free of any restrictions, to a new situation where 
biological organisms were now treated as sovereign possessions of 
the countries in which they occurred. In a post-Convention world, it 
was now legally mandated that benefits derived from natural sources 
be shared in an equitable manner with the country where the species 
was first collected. As many pharmaceuticals had historically been 
derived from natural sources at the time the Convention entered into 
force, it was anticipated that significant royalty payments would 
accrue to countries from which species that yielded bioactive 
compounds were derived. This anticipated flow of funds to 
developing countries that were home to the world’s richest 
biodiversity did not happen because of several difficulties that 
followed in the wake of the Convention. Immediately, there were 
problems determining what equity meant, what was the fair-market 
value of access to biodiversity, and what was the full range of 
benefits (which were later interpreted as much more than financial 
dividends that happened only following market entry for new 
products, with the expanded view of benefits including training, 
capacity building, and fully collaborative research opportunities).
8
 
The primary reason, however, that no major royalty payments 
flowed back to biodiversity-rich nations was that very few 
marketable discoveries were made. Though the FDA licensed new 
products in the period that followed the Convention entering into 
force, they had been discovered much earlier, were already in 
development, and had secured approval during the surge to evaluate 
natural products. For example, Taxol, derived from the Pacific Yew, 
Taxus brevifolia, was licensed for the treatment of refractory ovarian 
cancer in 1993, but it had been discovered more than ten years before 
the modern screening efforts began. The lack of anticipated 
discoveries may have been a consequence of several factors, one 
being that the twenty years following the Convention was simply too 
short a period of time for discoveries to work their way through the 
entire process of discovery, development, clinical testing, and 
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approval. It may be that given more time, some of the bioactive 
compounds discovered will eventually be developed and marketed. 
Or some of the advances in natural products chemistry from the 
discovered compounds may indirectly contribute to the future 
development of new drugs. It is widely perceived, however, in 
industry that the zenith of natural products screening was 
disappointing because not many therapeutically useful discoveries 
were made. It has been speculated that the lack of discoveries was not 
indicative of the promise of plants to yield new compounds, but 
rather a consequence of the limitations of methodology used to 
evaluate extracts.
9
 
The majority of natural products discovery in the 1980s and 1990s 
was attempted by evaluating crude extracts in bioassays.
10
 Crude 
extracts may contain in excess of 500 individual compounds. Many 
are present in very low concentrations, often too low to demonstrate 
any effect in a bioassay. Frequently, the compounds present in higher 
concentrations are tannins, lignans, and others known to interfere 
with or mask the activity of other compounds.
11
 By the mid-1990s, 
there was a trend toward fractionating crude extracts, but generally 
only into a small number of fractions and with the main goal of 
separating and removing the fraction that included the tannins. Ten 
years later in the mid-2000s, methods were described for partitioning 
fractions by separating them with chromotagraphic methods that 
create libraries of individual chemicals from extracts.
12
 Once 
individual compounds have been isolated, they can be evaluated at 
adequate concentrations and free from other compounds that may 
interfere, compete with, or mask their activity.
13
 One company, 
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Zinsser North America, offers automated units for the preparation of 
chemical libraries from crude natural products extracts. The intense 
natural products screening of the 1980s and 1990s should not be 
described as unproductive, but rather as having missed many 
potentially useful compounds that were never detected when 
screening complicated mixtures of chemicals in crude extracts. 
The criticism that the period of greatest interest in natural 
products was unproductive is unfounded, despite the fact that few 
drug candidates were identified. In the wake of the Convention, 
discovery efforts were conducted via international partnerships unlike 
anything that had existed before and these relationships led to great 
advances in basic field biology, pharmacology, and related fields. But 
perhaps the greatest impact of these relationships was to redefine 
international collaboration to be a much more equitable enterprise 
with more meaningful participation by all participants. Discovery 
programs were also conducted in a manner that addressed important 
concerns, such as insufficient research capacity in developing 
countries; major efforts supported by discovery programs helped train 
scientists, improve their research facilities, and provide support for 
economic development in communities living in close proximity to 
project areas. And finally, discovery programs provided another 
vehicle for promoting the importance of biodiversity and supporting 
its protection, an explicit goal of the ICBG programs.
14
  
During the 1980s and 1990s, the Missouri Botanical Garden (the 
“Garden”) was an active partner in numerous efforts to discover and 
developed new pharmaceutical, agricultural, nutritional, and various 
other kinds of products. All of the efforts were partnerships with 
outside discovery groups, and most of the programs included an 
international partner to facilitate work in other parts of the world. The 
Garden’s first effort began in 1986 and was a contract to provide 
plant samples from Africa and Madagascar to the NCI.
15
 This 
program led to what was probably the first international agreement 
for discovery programs, in this case guaranteeing benefits to 
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Madagascar through the NCI relationship.
16
 A drug discovery 
partnership with Monsanto began in 1990 and, shortly thereafter in 
1993, the Garden was a partner in one of the new NIH ICBGs.
17
 
Additional relationships expanded discovery efforts to look for new 
pesticides, genes for crop improvement, nutritional products, 
fragrances, and other commodities. Seven years after the Garden’s 
involvement in natural products discovery began, the Convention 
entered into force and international collecting agreements became a 
requirement.
18
 The Garden’s earlier agreements with African 
countries as part of the NCI collaboration were found to be fully 
compliant when signed, beginning in 1990. 
THE BENEFITS OF BIOPROSPECTING 
The most frequently discussed benefits from discovery of a new 
drug are financial benefits, generally milestone payments or 
royalties.
19
 One consequence of the lack of successful drug 
development from the bioprospecting surge is that the period is often 
regarded as having produced no tangible benefits. While the royalty 
payments originally envisioned did not materialize, the nonmonetary 
benefits that resulted from discovery efforts were numerous and of 
definite value to both developing countries and society in general.
20
 
These benefits include significant contributions to general 
knowledge; building research, development, and conservation 
capacity; improved quality of life for rural communities; and changes 
in the ethics of international collaboration. 
All natural products discovery programs require some form of 
collecting organisms in the wild and processing them for transport to 
the laboratories for evaluation. This collection requires basic 
biological skills, access to libraries and reference collection of 
specimens, and staff capable of accurately identifying the materials 
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collected. Biological specialists with a strong understanding of the 
group of organisms that they are collecting are especially important. 
This kind of expertise helps provide accurate identifications for the 
species being studied, helps prevent repeatedly sampling common 
species, and is essential for finding additional materials should a 
particular sample prove to be of enough interest to merit the 
collection of more material. All of the discovery programs during the 
bioprospecting surge trained scientists in the countries where they 
operated at least in the practice of gathering samples for evaluation 
and specimens that document those samples.
21
 Training was both 
formal and informal in the field and, in many cases, went beyond 
simple field methods to include identification, taxonomic study, and 
publication of new species. Additionally, discovery programs could 
only operate efficiently with access to sufficiently well-curated 
collections. The museums and herbaria of developing countries were 
often in rather poor condition, and programs helped rectify that 
situation by providing equipment and supplies. For example, the 
Garden’s NCI program financed the installation of air conditioning 
equipment in the national herbarium of Ghana as an essential step 
toward controlling insects in the collection. Most programs also 
provided extensive curatorial training in methods for management of 
research collections to the staff of the institutions where their in-
country work was based, and this education led to significant 
improvements in dozens of research institutions. All in all, discovery 
programs generally left collaborators that were better-educated and 
working in improved facilities. 
While the bioprospecting surge did not yield new drugs, hundreds 
of novel bioactive compounds were discovered, even though none 
made it through the whole development pipeline. The 
Suriname/Madagascar ICBG alone discovered many dozens of new 
compounds with bioactivity against one or another of the many 
bioassays testing multiple disease targets.
22
 While they may not have 
become new drugs, each new compound discovered added to our 
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general pharmacological knowledge in ways that may indirectly 
contribute to developing new therapies in the future. If parts of any of 
these plant-derived bioactive molecules were used to produce 
synthetic new drugs, it may not even be apparent that natural 
products contributed to the success. 
It has often been pointed out that while the world’s largely 
tropical, developing countries are home to the vast majority of the 
world’s biodiversity, they are notably short of adequately trained 
scientists and adequately funded research facilities.
23
 Addressing this 
lack of research capacity was one of the primary goals of the NIH 
ICBG projects. Every program included both formal and informal 
training as well as support for the improvement of in-country 
research facilities.
24
 During the first ten years of the Madagascar 
ICBG, the labs at the Centre National d’Application et des 
Recherches Pharmaceutiques were renovated, new equipment and 
supplies were obtained, and staff developed the capacity to evaluate 
plant extracts in a modern anti-malarial assay.
25
 Many field biologists 
initially trained as part of discovery efforts eventually found funding 
from other sources to continue their education. Improving research 
capacity in developing countries may be one of the greatest 
contributions from natural product discovery programs.
26
 
The collection of samples for evaluation was often based in small 
rural communities in close proximity to diverse tropical forests, and 
most of these communities were extremely poor. Discovery programs 
frequently provided at least temporary employment in communities 
where there we no jobs available. These programs also helped 
address some of the collateral consequences of poverty. In coastal 
villages in eastern Madagascar where malaria was rampant, the NCI 
program subsidized a mosquito net program that made repellant 
impregnated nets available at costs affordable to the local 
community, and malaria incidence in the community’s children fell 
dramatically. The Madagascar ICBG program supported an effort to 
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subsidize school supplies in the rural villages surrounding Zahamena 
National Park, making paper, notebooks, pens and pencils, and 
textbooks available to children who otherwise would not have had 
access to these essential items. 
Perhaps the greatest contribution that the bioprospecting surge 
was the Convention’s indirect influence on the ethics of international 
collaboration. The primary aim of the Convention was to establish 
systems that would capture benefits from the use of biological 
diversity, and one of those benefits was advancing science in 
biodiversity-rich developing countries.
27
 Post-Convention improved 
ethics for international partnerships were rapidly adopted across 
constituencies. It was no longer tolerable to go to another country and 
expect their scientists to support research efforts with little 
acknowledgement or benefit to themselves or their institutions. It 
rapidly became an accepted practice to require deposition of at least 
one complete set of collected specimens in some local museum or 
herbarium. The contributions of developing-world scientists were to 
be acknowledged via authorship as credit for real participation in the 
project. Today, field research is jointly planned and executed; 
publications acknowledge multiple coauthors; and institutional 
benefits, including funding, are shared more equitably. These 
changes in international collaboration constitute a tremendous 
contribution and, while not entirely attributable to discovery 
programs, they were an important consequence of the Convention.
28
 
The bioprospecting surge also contributed significantly to 
international conservation efforts. All partners in the discovery 
efforts of the time acknowledged that their success was dependent on 
access to biodiversity and that such access was essential to preserve 
the species on which this whole endeavor depended. The NCI 
program officers who spoke regularly at national and international 
professional meetings stressed the importance of conserving the full 
complement of species that had yet to be evaluated as possible drug 
sources. When the ICBG program was founded, conservation was an 
explicit goal of the original call for proposals, and the partnership that 
included the Garden also included Conservation International to 
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support direct conservation efforts. During the five years the program 
operated in Suriname, ICBG support contributed at least indirectly to 
efforts to secure protection for the Central Suriname Nature Reserve, 
which is now protected as a UNESCO World Heritage Site. Later in 
Madagascar, the same program helped secure protected status for 
Orangea, a forest in northeastern Madagascar that is rich in endemics 
but was rapidly being degraded and deforested. Together these 
conservation actions add another layer of justification for the 
preservation of biological diversity. 
CONCLUSION 
While the bioprospecting surge may not have yielded the much-
anticipated wealth of new drugs, the discovery projects that were 
conducted did result in numerous positive benefits. These included 
advancements in biological and pharmacological knowledge, 
capacity building in developing countries, economic benefits to poor 
rural communities, promotion of conservation of biological diversity, 
and influence on the ethics of international collaboration. These 
benefits accrued to individual scientists, the fields of biology and 
pharmacology in general, communities in developing countries, and 
humankind in the broadest sense. All of these advances contribute 
collectively, and will continue to do so in the future, to international 
scientific collaboration that is more equitable, helps address pressing 
economic issues in developing countries, and helps to promote the 
conservation of biological diversity. 
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